Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

36.81
+1.694.81%
Post-market: 36.980.1745+0.47%18:59 EST
Volume:416.58K
Turnover:15.16M
Market Cap:748.77M
PE:-4.66
High:37.26
Open:35.18
Low:34.47
Close:35.12
52wk High:66.92
52wk Low:6.48
Shares:20.34M
Float Shares:17.59M
Volume Ratio:0.61
T/O Rate:2.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.8997
EPS(LYR):-8.6765
ROE:-180.24%
ROA:-27.97%
PB:8.80
PE(LYR):-4.24

Loading ...

Company Profile

Company Name:
Nektar Therapeutics
Exchange:
NASDAQ
Establishment Date:
1990
Employees:
61
Office Location:
455 Mission Bay Boulevard South,San Francisco,California,United States
Zip Code:
94158
Fax:
415 339 5300
Introduction:
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Directors

Name
Position
Howard W. Robin
Director, President and Chief Executive Officer
Robert Chess
Chairman of the Board, Director
Diana Brainard
Director
Jeffrey R. Ajer
Director
R. Scott Greer
Director
Roy A. Whitfield
Director

Shareholders

Name
Position
Howard W. Robin
Director, President and Chief Executive Officer
Jonathan Zalevsky
Senior Vice President and Chief Research and Development Officer
Sandra Gardiner
Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Elizabeth Zhang
Vice President, Legal and Corporate Counsel